Close Menu

NEW YORK — Flow cytometry instrument developer Cytek Biosciences said on Thursday that it has raised $120 million in a Series D financing round.

The round was led by RA Capital and Hillhouse Capital with participation from OrbiMed and Lyfe Capital.

Cytek said that it will use the funding to expand its global infrastructure, as well as to expand its presence in the cell-analysis market in areas such as immunotherapy, immuno-oncology, and infectious disease.

In conjunction with the round, members of RA Capital and Hillhouse Capital have joined Cytek's board of directors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.